toxylact

The first professional lActological database in the word

Balsalazide (ATC A07EC04)

ATC class and general pharmacology

Balsalazide (balsalazide disodium) is classified under ATC code A07EC04, within the alimentary tract and metabolism group (A), antidiarrheals, intestinal anti-inflammatory/anti-infective agents (A07), intestinal anti-inflammatory agents (A07E), and the aminosalicylic acid and similar agents subclass (A07EC), alongside sulfasalazine (A07EC01), mesalazine (A07EC02), and olsalazine (A07EC03) (PubChem; Wikidoc). Marketed as Colazal (United States, capsule formulation) and Colazide/GIAZO (United Kingdom and a male-only tablet formulation, respectively), balsalazide is a prodrug in which the therapeutically active moiety, mesalamine (5-aminosalicylic acid, 5-ASA), is joined via an azo bond to an inert carrier molecule, 4-aminobenzoyl-β-alanine (4-ABA) — a structural design that, like olsalazine, dispenses entirely with the sulfapyridine carrier used in sulfasalazine (DrugBank; Wikipedia). Each 750 mg balsalazide disodium capsule is equivalent to 267 mg of mesalamine, while the GIAZO tablet formulation contains 1.1 g of balsalazide disodium per tablet (DailyMed; FDA label — GIAZO).accessdata.fda+5

Following oral administration, the acid-insoluble balsalazide molecule remains largely intact through the stomach and small intestine, preventing premature systemic release of 5-ASA in the upper gastrointestinal tract. Upon reaching the colon, indigenous anaerobic bacterial flora produce azoreductase enzymes that cleave the azo bond, liberating equimolar quantities of 5-ASA and the inert carrier 4-ABA; both moieties undergo further N-acetylation to yield N-acetyl-5-ASA (N-Ac-5-ASA) and N-acetyl-4-ABA (N-Ac-4-ABA), respectively (FDA label — GIAZO; biomedicus.gr). This delivery mechanism achieves colonic delivery of more than 99% of the administered 5-ASA dose, a proportion exceeding that of pH-dependent mesalamine formulations, and systemic absorption of the intact parent drug is very low, with less than 1% recovered unchanged in urine (PMC — pediatric pharmacokinetics study; Hale's Lactation database, as cited). Pharmacokinetic parameters for the disodium salt include a time to maximum concentration (Tmax) of 1–2 hours, an elimination half-life of approximately 1.9 hours, plasma protein binding of approximately 99%, and a molecular weight of 437 daltons.accessdata.fda+3

The precise anti-inflammatory mechanism of 5-ASA remains incompletely characterised but is understood to act locally at the colonic mucosa rather than systemically. Mucosal production of arachidonic acid metabolites — through both the cyclooxygenase pathway (prostanoids) and the lipoxygenase pathway (leukotrienes and hydroxyeicosatetraenoic acids) — is elevated in chronic inflammatory bowel disease, and 5-ASA is believed to attenuate inflammation by inhibiting both cyclooxygenase and lipoxygenase enzymes, thereby blocking production of these mediators in the colon (DrugBank; PubChem). Because systemic absorption of both the parent drug and its active metabolite is not required for therapeutic efficacy, balsalazide is associated with a reduced systemic side-effect burden relative to sulfasalazine and demonstrates a faster onset of action than mesalamine in some comparative analyses (PubMed — therapeutic review; PMC — pediatric pharmacokinetics study).pubchem.ncbi.nlm.nih+3

Balsalazide (Colazal) is indicated for the treatment of mildly to moderately active ulcerative colitis in adults and children five years of age and older, while the GIAZO tablet formulation carries a narrower indication restricted to male patients eighteen years of age and older (MedlinePlus; FDA label — GIAZO). Standard adult dosing of balsalazide disodium capsules is typically administered without regard to meals, in contrast to some other aminosalicylates.medlineplus+2

Toxicological profile

Across four controlled clinical trials, patients receiving balsalazide 6.75 g/day most frequently reported headache (8%), abdominal pain (6%), diarrhoea (5%), nausea (5%), vomiting (4%), respiratory tract infection (4%), and arthralgia (4%); withdrawal from therapy due to adverse reactions was comparable between balsalazide and placebo groups. In a dedicated paediatric trial enrolling 68 patients aged 5 to 17 years treated with balsalazide 6.75 g/day or 2.25 g/day for eight weeks, the most frequently reported adverse reactions were headache (15%), upper abdominal pain (13%), abdominal pain (12%), vomiting (10%), diarrhoea (9%), ulcerative colitis exacerbation (6%), nasopharyngitis (6%), and pyrexia (6%) — a profile broadly similar to that observed in adults (PMC — pediatric pharmacokinetics study; DailyMed).pmc.ncbi.nlm.nih+1

As with all aminosalicylates, balsalazide can precipitate a mesalamine-induced acute intolerance syndrome — clinically indistinguishable at onset from an exacerbation of ulcerative colitis — characterised by cramping, acute abdominal pain, bloody diarrhoea, and sometimes fever, headache, and rash; although the exact frequency in balsalazide-treated patients has not been separately determined, this syndrome has occurred in approximately 3% of patients in controlled trials of mesalamine or sulfasalazine, and prompt discontinuation is warranted if suspected (DailyMed; Mayo Clinic). Patients with a prior hypersensitivity reaction to sulfasalazine may exhibit a similar reaction to balsalazide or other mesalamine-derived compounds, potentially presenting with internal organ involvement including myocarditis, pericarditis, nephritis, hepatitis, pneumonitis, and haematologic abnormalities. Severe cutaneous adverse reactions — Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalised exanthematous pustulosis (AGEP) — have also been reported with mesalamine, the active moiety of balsalazide (DailyMed; Cleveland Clinic).mayoclinic+2

Renal toxicity associated with 5-ASA compounds, including balsalazide, may manifest as interstitial nephritis, nephrotic syndrome, or renal failure, and cases of nephrolithiasis have been reported, including stones composed of 100% mesalamine content that are notably radiotransparent and undetectable by standard radiography or computed tomography — adequate fluid intake during treatment is recommended to mitigate this risk (DailyMed; biomedicus.gr). Notably, and in contrast to the pronounced preclinical nephrotoxic signal documented for olsalazine, dedicated animal toxicology studies of balsalazide at oral doses up to 2,000 mg/kg — approximately 21 times the recommended 6.75 g/day human dose on a mg/kg basis — demonstrated no nephrotoxic effects in rats or dogs, suggesting a comparatively more favourable preclinical renal safety margin for balsalazide within the aminosalicylate class, even though clinical renal toxicity signals in human use remain documented, albeit described as rare (DailyMed; Crohn's & Colitis Foundation).crohnscolitisfoundation+2

Hepatic adverse effects reported with balsalazide encompass hepatotoxicity, elevation of hepatic enzymes (AST, ALT, GGT, LDH, alkaline phosphatase, bilirubin), jaundice, cholestatic jaundice, cirrhosis, hepatocellular damage including liver necrosis and liver failure, and a Kawasaki-like syndrome with hepatic dysfunction. Additional documented effects include pancreatitis, alopecia, pruritus, photosensitivity, and harmless reddish-brown urine discoloration occurring ex-vivo upon contact with bleach-treated surfaces or toilet water (DailyMed; MedicalNewsToday). A specific paediatric warning applies to recent varicella (chickenpox) vaccination: balsalazide should not be administered within six weeks of vaccine receipt owing to a theoretical risk of Reye's syndrome.medlineplus+2

No case of overdose has been reported with Colazal in clinical use; a single documented case of accidental overdose with a related mesalamine product involved a three-year-old child who ingested 2 g and was treated with ipecac and activated charcoal without adverse sequelae. In animal studies, a single oral dose of balsalazide disodium at 5 g/kg, or of the 4-ABA metabolite at 1 g/kg, was non-lethal in mice and rats, with no symptoms of acute toxicity observed at these doses (DrugBank; FDA Clinical Review — Colazal). Because balsalazide is an aminosalicylate, theoretical human overdose is expected to mirror classic salicylate toxicity — nausea, vomiting, abdominal pain, tachypnoea, hyperpnoea, tinnitus, and neurologic symptoms including headache, dizziness, confusion, and seizures — with severe intoxication potentially producing electrolyte and acid-base disturbance and secondary renal or hepatic damage. No specific antidote exists; management is supportive, including gastrointestinal decontamination, correction of fluid and electrolyte imbalance, and maintenance of adequate renal function.fda+2

Lactation pharmacology and infant exposure

Direct pharmacokinetic data on the excretion of intact balsalazide into human milk are not currently available in the published literature (LactMed/NCBI Bookshelf; Drugs.com Breastfeeding Monograph). However, because balsalazide is rapidly and almost completely converted to its active metabolite mesalamine within the colon, with systemic absorption of the intact parent compound being very low (oral bioavailability under 1%, plasma protein binding approximately 99%), its lactational risk profile is assessed largely by extrapolation from the well-characterised pharmacokinetics of mesalamine itself, supplemented by direct clinical observation of balsalazide-exposed infants (e-lactancia.org; Hale's Lactation database, as cited).pubmed.ncbi.nlm.nih+2

Mesalamine itself is known to be poorly excreted into breast milk, with negligible transfer of the parent 5-ASA molecule, though comparatively higher concentrations of the inactive metabolite N-acetyl-5-ASA have been documented in milk, the clinical significance of which for the breastfed infant remains undefined (LactMed/NCBI Bookshelf, Mesalazine entry; e-lactation). A small number of diarrhoea cases have been reported in infants exposed to mesalamine derivatives via breast milk, although the overall rate has not been found to be high, and a case-control review of 121 exposed infants against 121 unexposed controls failed to observe a statistically significant difference in adverse outcomes between groups (Moretti, 1989). Specific to balsalazide, one directly attributable case has been documented: the active metabolite of balsalazide (mesalamine) was considered probably responsible for diarrhoea in a six-week-old infant, with the diarrhoea recurring on four separate occasions following four successive maternal drug rechallenges during breastfeeding — a dechallenge-rechallenge pattern that provides comparatively strong causal evidence for this specific adverse outcome, notwithstanding its apparent rarity (Drugs.com Breastfeeding Monograph; PubMed/LactMed).ncbi.nlm.nih+3

Hale's Lactational Risk Categorisation classifies balsalazide as L3 ("Limited Data–Probably Compatible"), reflecting the absence of dedicated balsalazide-specific milk transfer studies combined with a favourable inference drawn from its very low oral bioavailability and the broader mesalamine safety record (Hale's Lactation database, as cited). Because balsalazide, like olsalazine, employs an inert non-sulfonamide carrier molecule (4-aminobenzoyl-β-alanine) rather than sulfapyridine, it carries none of the sulfonamide-associated theoretical risks relevant to the neonatal breastfed infant, such as haemolysis in glucose-6-phosphate dehydrogenase (G6PD)-deficient infants or displacement of bilirubin from albumin-binding sites with attendant kernicterus risk — considerations that remain specifically relevant to sulfasalazine but not to balsalazide (e-lactation; DrugBank).drugbank+1

Lactological safety assessment and clinical recommendations

Independent lactation-risk reference systems (e-lactancia/e-lactation) classify balsalazide at their lowest risk category — "very low risk," compatible with breastfeeding, and not considered risky for the infant — noting explicitly that no alternative agent is proposed, since balsalazide is assessed as relatively safe in its own right (e-lactation; e-lactancia.org). This classification is supported by a broad base of expert consensus (Torres 2023, Russell 2023, Nguyen 2016, McConnell 2016, Mahadevan 2015, van der Woude 2015, Nielsen 2014) affirming the general compatibility of mesalamine and its various prodrugs — including balsalazide, olsalazine, and sulfasalazine — with breastfeeding. The Crohn's & Colitis Foundation independently corroborates a "low risk" categorisation for balsalazide during lactation, specifically flagging the absence of dedicated human milk-transfer data alongside the theoretical potential for infant diarrhoea as the principal residual consideration.crohnscolitisfoundation+2

Based on the convergent pharmacokinetic inference, the documented clinical case history, and expert consensus, the following lactological safety assessment and clinical recommendations are proposed:

  • Overall risk categorisation: Very low to low risk to the term, healthy breastfed infant. The very limited systemic bioavailability of intact balsalazide, combined with the well-established low transfer of its active mesalamine metabolite into breast milk, supports continuation of breastfeeding during maternal balsalazide therapy (LactMed/NCBI Bookshelf; e-lactancia.org).pubmed.ncbi.nlm.nih+1
  • Continuation of breastfeeding: Consistent with LactMed's explicit guidance, maternal use of balsalazide is not, on current evidence, a reason to discontinue breastfeeding; mothers requiring balsalazide for maintenance of ulcerative colitis remission should be supported to continue nursing while receiving the medication.pubmed.ncbi.nlm.nih
  • Infant clinical monitoring: Breastfed infants should be observed for diarrhoea specifically, given the directly documented dechallenge-rechallenge case establishing a plausible causal link between maternal balsalazide (via its mesalamine metabolite) and infant gastrointestinal symptoms; any onset of loose stools, feeding intolerance, or dehydration signs in the infant should prompt paediatric evaluation and consideration of a temporal relationship to maternal dosing.drugs
  • Rechallenge considerations: Where infant diarrhoea has occurred and resolved upon maternal drug discontinuation, clinicians should be aware — as illustrated in the documented case — that symptoms may recur upon rechallenge; this pattern warrants a cautious, individualised risk-benefit discussion should continued maternal therapy be considered essential despite recurrent infant symptoms.drugs
  • Distinguishing infant diarrhoea aetiology: Given the base-rate prevalence of infantile diarrhoea from unrelated causes (infection, dietary transition, other exposures), clinicians should consider maternal aminosalicylate exposure as one differential among several rather than an automatic cause, reserving drug discontinuation for cases with a clear temporal association or confirmed recurrence upon rechallenge.e-lactation
  • Preference within the aminosalicylate class: For lactating patients requiring an aminosalicylate who are intolerant of sulfasalazine, balsalazide represents a pharmacologically reasonable option, sharing with olsalazine the absence of a sulfapyridine carrier and its associated haemolysis/kernicterus risks; however, given the comparative paucity of balsalazide-specific human milk pharmacokinetic data relative to mesalazine and olsalazine, mesalazine or olsalazine may be preferable when equally clinically appropriate, given their more extensively documented direct milk-transfer profiles (LactMed/NCBI Bookshelf, Mesalazine entry; e-lactancia.org).ncbi.nlm.nih+1
  • Maternal monitoring independent of lactation status: Given the clinically documented, albeit rare, potential for renal, hepatic, and hypersensitivity-related adverse effects with balsalazide, periodic assessment of maternal renal and hepatic function, together with vigilance for hypersensitivity or acute intolerance syndrome, remains prudent during lactation, consistent with general aminosalicylate-class monitoring recommendations irrespective of breastfeeding status.dailymed.nlm.nih
  • Dose considerations: No lactation-specific dose adjustment has been established for balsalazide; the standard indicated dose should be used as clinically required, since dedicated dose-proportionality data for lactational milk transfer are not available.medlineplus

In summary, balsalazide's pharmacokinetic profile — characterised by minimal systemic absorption of the intact prodrug and reliance on the well-documented low mesalamine milk-transfer pathway — together with expert consensus support and a favourable overall risk classification, supports its compatibility with breastfeeding, with targeted infant monitoring for diarrhoea recommended given the one directly documented causal case in the literature.

Recent ARTICLES

July 24

Abdominal Compartment Syndrome

PWhile the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 18

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

July 14

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.